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a  b  s  t  r  a  c  t
Myotonic  dystrophy  (DM1)  is  a multisystemic  disease  caused  by an  expansion  of  CTG repeats  in  the  region
of  DMPK,  the  gene  encoding  DM  protein  kinase.  The  severity  of  muscle  disability  in DM1 correlates
with  the size  of  CTG expansion.  As respiratory  failure  is one  of  the  main  causes  of  death  in DM1,  we
investigated  the  correlation  between  respiratory  impairment  and  size  of the  (CTG)n  repeat  in  DM1  animal
models.  Using  pressure  plethysmography  the respiratory  function  was assessed  in  control  and  transgenicM1  transgenic mice
TG trinucleotide
ressure plethysmography
mice  carrying  either  600  (DM600)  or >1300  CTG  repeats  (DMSXL).  The  statistical  analysis  of  respiratory
parameters  revealed  that  both  DM1  transgenic  mice  sub-lines  show  respiratory  impairment  compared
to  control  mice.  In  addition,  there  is  no signiﬁcant  difference  in  breathing  functions  between  the  DM600
and  DMSXL  mice.
In  conclusion,  these  results  indicate  that respiratory  impairment  is present  in both  transgenic  mice
sub-lines,  but  the severity  of  respiratory  failure  is  not  related  to the  size  of  the  (CTG)n  expansion.. Introduction
Myotonic dystrophy type 1 is one of the most common
utosomal dominant muscular dystrophies and results from the
xpansion of a cytosine-thymine-guanine (CTG) nucleotide repeat,
ocated in the 3′-untranslated region of the DMPK gene located on
hromosome 19. Normal individuals have ≤30 copies of this CTG
epeat but in DM1  the number varies from 50 to >3000 (Brook et al.,
992; Fu et al., 1992; Harley et al., 1993; Mahadevan et al., 1992).
ildly affected, late-onset DM1  patients carry alleles with 50–150
epeats, while juvenile and adult-onset patients have 100–1000
TG repeats (Hunter et al., 1992; Novelli et al., 1993). For unknown
easons, the mutation becomes unstable and the number of repeats
ends to increase from generation to generation, accounting for
enetic anticipation and the congenital DM form (CDM). Anticipa-
ion is a typical feature of DM1  and corresponds to the increasing
everity in successive generations with earlier age at onset. Individ-
als with CDM can have more than one thousand repeats (Ashizawa
t al., 1992; Lavedan et al., 1993; Mahadevan et al., 1992; Salehi
t al., 2007; Tsilﬁdis et al., 1992).
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The main clinical manifestations of the juvenile and adult form
of DM1  are muscle weakness and myotonia. CDM is characterized
by a delay in skeletal muscle and brain development, muscular
weakness and atrophy with hypotonia (Harper, 2001; Meola, 2000).
Although DM1  is characterized mostly by muscle dysfunction, it is
a multisystemic disease with various degrees of severity. Several
clinical reports emphasized that acute and chronic respiratory fail-
ure is one of the major and potentially life-threatening features of
DM1  patients. A transgenic mouse model of DM1  carrying a large
CTG triplet expansion also shows respiratory impairment (Panaite
et al., 2013). Genotype–phenotype correlation was  reported in sev-
eral studies (Gennarelli et al., 1996; Harley et al., 1993; Hunter et al.,
1992; Jaspert et al., 1995; Novelli et al., 1993; Salehi et al., 2007),
however, a systematic correlation between the size of CTG repeat
and DM1  manifestations are debatable (Marchini et al., 2000). In
the present study we investigate the relationship between the size
of CTG repeat and the severity of the respiratory impairment by
analysing breathings function in DM1  transgenic mice carrying
either 600 or more than 1300 CTG repeats (Gomes-Pereira et al.,
2007; Panaite et al., 2011; Seznec et al., 2000).2. Materials and methods
All experimental protocols were reviewed and approved by the
institutional animal care and use committee.
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tig. 1. Representative pressure plethysmography tracings for wild type control mice
nd  anesthetized mice. The representative tracings illustrate the changes in the bre
onscious mice, and the lower amplitude and frequency in anaesthetized mice.
.1. Generation of transgenic mouse models for DM1
Transgenic mice carrying the human genomic DM1  region with
n expanded repeat of approximately 600 CTG trinucleotides and
isplaying a mild DM1  phenotype have been described previ-
usly (Seznec et al., 2000). The mice were of mixed background
>90% C57BL/6 background) and carried about 600 CTG repeats
DM600 mice). By breeding heterozygous mice, homozygous and
ild type mice are obtained from the same litter. Recently, DMSXL
ice carrying more than 1300 CTG repeats were obtained from
M600 mice after large expansions of the CTG repeat over suc-
essive generations (Gomes-Pereira et al., 2007). Expression of
xpanded CUG leads to the formation of numerous foci that colo-
alize with muscle-blind-like proteins 1 and 2 (MBNL1 and MBNL2)
nd are sequestered in the nuclei. Mild missplicing of target RNA
s observed in muscle and heart tissue. The molecular features of
M1-associated RNA toxicity are associated with high mortality,
rowth retardation and muscle defects (abnormal histopathology,
educed muscle strength and lower motor performances) (Huguet
t al., 2012). Only homozygous transgenic mice were used in our
tudy since the heterozygous mice expressing a low level of DMPK
ranscripts have no obvious phenotype. Fifteen mice aged 5 months
ere analysed: 5 wild type control mice (body weight 33.8 ± 3.6 g);
 DM600 transgenic mice (body weight 23.8 ± 01.3 g) and 5 DMSXL
ransgenic mice (body weight 22.2 ± 2.0 g).
.2. Assessment of mice breathing function by pressure
lethysmography
Breathing function was assessed in wild type and transgenic
ice (DM600 and DMSXL) by pressure plethysmography, a precise
ethod adapted for both awake and anaesthetized small animals
Glaab et al., 2001; Stunden et al., 2001; Yilmaz et al., 2005).
rieﬂy, each conscious mouse was ﬁrstly weighed then placed in
 Respiromax cylindrical chamber (Respiromax system, Columbus
nstruments, Columbus, OH, USA), while the head of the animal
rotruded through an inﬂatable latex cuff into the head-exposure
hamber, which was ventilated by a continuous airﬂow. The animal
as prevented from moving and held in position by shifting the
ail rod. Each mouse was allowed to acclimatize to the plethys-
ography chamber for approximately 5 min  before tests began.
hroughout the testing period a sensitive transducer continuously
easured the changes in pressure in the body chamber caused by
he animal’s respiration. Signals from the pressure transducer wereransgenic mice (DM600 and DMSXL). The breathing trace was  recorded in conscious
 pattern in transgenic mice compared to control mice. Note the lower amplitude in
ampliﬁed and digitized by an acquisition board on a computer. A
respiratory function software (Columbus Instruments) displayed
the graphic of the pressure variations, calculated the respiratory
parameters and stored the data for subsequent statistical analysis.
The following parameters were automatically calculated and
analysed: tidal volume (TV, ml), respiratory rate (RR, breaths per
minutes) and minute volume (MV, tidal volume multiplied by
respiratory rate, ml/min). In another series of experiments, respira-
tory function was  measured in mice anaesthetized with isoﬂurane
using a MatrxTM Quantiﬂex VMC® low ﬂow anaesthesia system
(Midmark, Versailles, OH, USA). Animals were placed individually
in an induction chamber, and anaesthesia was  induced with 5%
isoﬂurane in a gas mixture of O2/N2O2 (30%/70%) which does not
prevent spontaneous breathing. The animals were then quickly
placed inside the Respiromax system, with a 1.5% isoﬂurane ﬂow
in the head chamber in the same O2/N2O2 gas mix. Animals were
allowed to settle for 5 min  before the ﬁrst set of measurements. In
all experiments the temperature of the body chamber was  contin-
uously monitored using a thermal probe. The following parameters
were calculated and analysed: tidal volume (TV, ml), respiratory
rate (RR, breaths per minutes), minute volume (MV, tidal volume
multiplied by respiratory rate, ml/min). The respiratory function
of each mouse was tested several times over a period of 2 weeks.
2.3. Statistical analysis
Values for all measurements were expressed as the
mean ± standard deviation (SD). Each respiratory parameter (TV,
RR, MV,  MV/g, heart rate, oxygen saturation) for each mouse was
analysed and compared. ANOVA was  used to determine signiﬁcant
differences between the groups, followed by Bonferonni–Holm
post hoc test, and pair-groups were compared by Student’s t-test.
In all cases, plethysmograph data were normalized to the weight
of the animal. Values are reported as mean ± SD. P < 0.05 was
considered as a signiﬁcant difference. All statistical analyses were
performed using GraphPad Prism software (GraphPad Software
Inc., La Jolla, CA, USA).
3. ResultsTo investigate whether the severity of respiratory problems is
correlated with the size of the CTG triplet, we  measured and com-
pared, under the same experimental conditions, the respiratory
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Table  1
Mean values of respiratory parameters measured in anesthetized 5–6 months wild type and DM1  transgenic mice (n = 5).
Respiratory parameter Wild-type DM600 DMSXL P1 P2 P3
BW  = 33.8 ± 3.6 g BW = 23.8 ± 01.3 g BW = 22.2 ± 2.0 g
RR 125.7 ± 14.4 94.5 ± 9.9 87.8 ± 5.3 <0.01 <0.01 ns
TV  (ml) 0.381 ± 0.041 0.234 ± 0.022 0.228 ± 0.013 <0.01 <0.01 ns
MV  (ml) 47.72 ± 11.01 21.96 ± 1.36 20.48 ± 1.33 <0.01 <0.01 ns
TV/BW (ml/g) 0.011 ± 0.001 0.010 ± 0.002 0.010 ± 0.001 ns ns ns


















































dR = respiratory rate; TV = tidal volume; MV  = minute volume; BW = body weight. P1
ice;  P3: comparisons between DM600 and DMSXL mice; ns = non signiﬁcant. P < 0
unction in wild type control mice and in two transgenic mice
ub-lines carrying either about 600 or more than 1300 CTG repeats.
First we assessed respiratory function in conscious mice. In all
xperiments we  noticed that the breathing pattern recorded in con-
cious wild type control mice differed from that in both transgenic
ice sub-lines (Fig. 1). Also, respiratory tracings in DM600 trans-
enic mice were comparable to those recorded in DMSXL mice.
he statistical analysis of the most relevant respiratory parameters
evealed that the mean values of the respiratory rate (RR), tidal
olume (TV) and volume per minute (MV) were similar in both
ransgenic mice sub-lines, but were different from those measured
n wild type control mice, which indicates a change in breathing
unction in transgenic mice.
During measurements we observed that conscious mice, specif-
cally conscious transgenic mice, displayed a certain amount of
gitation and stress which probably biased the evaluation of respi-
atory function in these mice. Therefore, the breathing function was
ssessed in anaesthetized mice. Under anaesthesia, the respiratory
arameters measured over short and extended time periods pro-
ided reproducible values in all transgenic and control mice. The
racing of several repetitive measurements again showed that the
espiratory pattern in both transgenic mice sub-lines was differ-
nt (lower amplitudes and frequency) from that found in wild type
ontrol mice, but the breathing pattern was identical in DM600 and
MSXL mice (Fig. 1).
Detailed statistical analysis of the RR, TV, and MV  demonstrated
he presence of signiﬁcant changes in respiratory function between
he wild type control and transgenic mice sub-lines. Speciﬁcally,
he RR, TV and MV were signiﬁcantly decreased in both transgenic
ice compared to wild type mice (Table 1). Consequently, the mean
alue for minute volume/body weight (Tidal volume X breathing
requency/body weight) was also reduced in DM600 and DMSXL
ice. In addition, the statistical analysis conﬁrmed the absence
f a signiﬁcant difference in the respiratory parameters between
M600 and DMSXL mice. The observed decrease in the RR, TV and
V in the both transgenic mice sub-lines indicated the presence of
espiratory impairment in these mice.
. Discussion
In DM1, the muscles, heart, brain, eye, endocrine, respiratory
nd gastroenteric systems are involved with variable levels of
everity (Romeo, 2012). For example cataracts, cardiac conduction
efects, respiratory failure, and changes in the CNS with mental
etardation are recognized as common extramuscular manifesta-
ions in patients with DM1. Sleep disorders including excessive
aytime sleepiness and nocturnal respiratory events are also
rominent in patients affected by DM1. Sleep disturbances have
epeatedly been reported as one of the earliest symptoms of DM1
nd may  represent a marker of central nervous system neurode-
enerative processes in DM1  (Laberge et al., 2004, 2013; Phillips
t al., 1999; Romigi et al., 2011). An abnormal expanded CTG trin-
cleotide repeat in the 3′-untranslated region of the myotonic
ystrophy protein kinase (DMPK) gene is the genetic basis forparisons between WT and DM600 mice; P2: comparisons between WT  and DMSXL
as considered signiﬁcant.
DM1  (Fu et al., 1992; Mahadevan et al., 1992). Over a threshold of
between 40 and 50 CTG repeat nucleotides, the mutation becomes
unstable and after three to four generations the CTG repeat can
become very long, leading to the congenital form of the disease
when transmitted by the mother (Ashizawa et al., 1992; Harley
et al., 1993; Lavedan et al., 1993; Tsilﬁdis et al., 1992). Although
the muscular disability becomes more severe and frequent in the
CDM patients, the severity of other manifestations of the disease
is still a debatable issue (Botta et al., 2008; Gennarelli et al., 1996;
Jaspert et al., 1995; Marchini et al., 2000; Novelli et al., 1993; Perini
et al., 1999; Winblad et al., 2006). In fact, genotype-phenotype cor-
relation studies have reported a relationship between the size of
the CTG repeat in lymphocyte DNA and the severity of muscu-
lar disability as well as nervous system and gonadal dysfunction
(Jaspert et al., 1995; Kinoshita and Hirose, 1999; Logigian et al.,
2004). An association between the CTG repeat size and cognitive
impairment has also been described (Sistiaga et al., 2010; Winblad
et al., 2006). A relation between the severity of cardiac arrhyth-
mia  as well as conduction abnormalities and CTG repeat length has
been noticed in DM1  patients (Finsterer et al., 2001). Furthermore,
another study has concluded that measurement of triplet expan-
sions in patients’ lymphocyte DNA is highly valuable and accurate
for prognostic assessment (Gennarelli et al., 1996). While these
studies support the presence of a correlation between the sever-
ity of certain DM1  features and the size of CTG triplet, other studies
have shown controversial results. The clinical examination of 24
DM1  patients aged between 18 and 64 years old from 14 unre-
lated families showed that respiratory insufﬁciency, diabetes and
cataract were not related to the size of the CTG repeat detected in
blood cells (Marchini et al., 2000). Also, analysing CTG repeats and
electrocardiographic recordings in the same DM1  patients revealed
no correlation between the repeat number and cardiac abnormal-
ities (Rakocevic-Stojanovic et al., 2003). In addition, no signiﬁcant
correlation was found between the severity of sleep disorders and
genetic size of CTG repeat (Laberge et al., 2004; Marchini et al.,
2000; Romigi et al., 2011). Recent results of an extensive genotype-
phenotype study performed on 2650 patients have emphasized
that great care should be taken in inferring too much from the leu-
cocyte CTG repeat number in a clinical diagnostic prediction (Salehi
et al., 2007). Therefore, the correlation between the size of CTG
repeat and DM1  manifestations is still unclear.
Clinically respiratory and cardiac problems have long been rec-
ognized as the main complications of DM1  patients. Large cohort
studies have reported that in adult onset DM1  respiratory problems
are the leading causes of death (around 40%) (de Die-Smulders et al.,
1998; Groh et al., 2008; Mathieu et al., 1999). In the CDM, only
50% of patients survive to their mid  30s and the death of about
66% of surviving patients is due to respiratory causes (Reardon
et al., 1993). As the correlation between genotype and respira-
tory problems has remained unclear, we set out in the present
study to measure and compare the breathing functions in two
DM1  transgenic mouse sub-lines: (i) DM600 transgenic mice car-
rying about 600 CTG triplet and displaying a mild DM1  phenotype
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rinucleotide repeats (>1300) and expressing a more severe muscu-
ar disability demonstrated by the formation of numerous nuclear
oci that colocalize with muscleblind-like protein 1 and 2 (MBNL1
nd MBNL2), mild missplicing of target RNA in muscle and heart
issue, high mortality, growth retardation and muscle and brain
efects (Gomes-Pereira et al., 2007; Hernandez-Hernandez et al.,
013; Huguet et al., 2012; Panaite et al., 2011; Reardon et al., 1993).
he results of our present study revealed two important points: (i)
he presence of respiratory impairment in DM600 mice as well as in
MSXL mice; (ii) the respiratory deﬁciency does not become more
evere in DMSXL mice which have a larger number of CTG repeats.
he two transgenic mice sub-lines display equal respiratory impair-
ent characterized by a signiﬁcant decrease in the most relevant
espiratory parameters compared to control animals. The respira-
ory impairment detected in DM1  transgenic mice is not caused by
heir small weight as previously we have shown that control mice
ith similar size and weight to DM1  mice do not show respiratory
ailure (Panaite et al., 2013). The absence of a signiﬁcant difference
n breathing parameters between DM600 and DMSXL mice is in
ine with our previous morphological and morphometric results
Panaite et al., 2008, 2013). Indeed, similar pathological changes in
iaphragmatic neuromuscular junctions (NMJs) and phrenic nerves
ere detected in both DM600 and DMSXL mice compared to con-
rol mice. In both transgenic mice sub-lines a denervation rate of
bout 20% of the end-plates (EPs) was calculated and an identical
eduction in the size, shape complexity and density of acetylcholine
eceptors in EPs was measured. In addition, a loss of about 40%
f the number of unmyelinated phrenic afferents was observed
n both DM600 and DMSXL transgenic mice (Panaite et al., 2008,
013). In conclusion, the DM600 and DMSXL mice have a similar
espiratory failure indicating that there is no relationship between
he severity of the respiratory problems assessed in these mice
nd the size of CTG triplet. This is consistent with some clini-
al studies reporting that the respiratory and cardiac insufﬁciency
s not related to the number of CTG repeats detected in blood
ells of DM1  patients. The examination of 24 DM1  subjects having
 variable number of CTG repeats (50–2200) demonstrated that
espiratory failure is present in DM1  patients with small num-
ers of CTG repeats as well as in patients with higher numbers of
epeats. Moreover, the respiratory impairment does not become
ore severe in patients with large CTG expansions (Marchini et al.,
000; Rakocevic-Stojanovic et al., 2003). The authors emphasize
hat the severity of single, but not all DM1  clinical manifesta-
ions may  correlate with the size of CTG triplet in peripheral blood
ells. To explain why the size of CTG repeats correlates with the
everity of some but not all DM1  clinical manifestations, several
echanisms are suggested. Among the mechanisms that could be
nvolved in this phenomenon is the reduction in the expression
f genes neighbouring the ampliﬁed CTG repeat or sequestration
f nuclear CUG binding proteins (Marchini et al., 2000). More-
ver, nuclear accumulations of toxic expanded DMPK gene may be
esponsible for aberrant genes expression in modifying alternative
plicing in brain/brainstem (Laberge et al., 2013). Another mecha-
ism is the somatic mosaicim with different ampliﬁcation rates in
he various tissues (Jaspert et al., 1995). It is probable that in DM1
nimal model one or all these mechanisms may  play a role.
. Conclusions
The measurement of respiratory function in DM1  transgenic
ice carrying either 600 or more than 1300 CTG repeats showedhat the respiratory impairment is present in both transgenic mice
ub-lines. In addition the respiratory failure does not become more
evere in transgenic mice harbouring a greater number of CTG
epeats. These results show that in the DM1  animal model therey & Neurobiology 189 (2013) 22– 26 25
is no correlation between the severity of respiratory impairment
and the size of CTG triplet. The fact that DM1  transgenic mice
demonstrate, as patients with DM1, that muscle damage but not
respiratory failure is correlated to CTG expansion size, provides fur-
ther evidence of the validity of the DM1  animal model which can
be used to study different mechanisms underlying DM1.
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